Holen Sie sich die Stockscreener-App
121.43
0.21%
0.25
Vorhandelsmarkt:
120.51
-0.92
-0.76%
Schlusskurs vom Vortag:
$121.18
Offen:
$121.47
24-Stunden-Volumen:
518.02K
Relative Volume:
0.88
Marktkapitalisierung:
$7.34B
Einnahmen:
$3.99B
Nettoeinkommen (Verlust:
$463.16M
KGV:
17.10
EPS:
7.1
Netto-Cashflow:
$1.10B
1W Leistung:
-1.24%
1M Leistung:
-1.25%
6M Leistung:
+11.39%
1J Leistung:
+4.20%
1-Tages-Spanne:
$120.06
$122.38
1-Wochen-Bereich:
$120.06
$124.66
52-Wochen-Spanne:
$99.06
$134.17
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Vergleichen Sie JAZZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
121.43 | 7.34B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Perpetual Ltd - MarketBeat
45,463 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by Lmcg Investments LLC - MarketBeat
MassMutual Private Wealth & Trust FSB Acquires 17,681 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
2,442 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by Aaron Wealth Advisors LLC - MarketBeat
5,811 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by Arkadios Wealth Advisors - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Update - MarketBeat
Kera Capital Partners Inc. Invests $288,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Wedge Capital Management L L P NC Sells 48,679 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Empirical Asset Management LLC Invests $5.36 Million in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Hennion & Walsh Asset Management Inc. - MarketBeat
Burney Co. Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline - MSN
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
JAZZ (Jazz Pharmaceuticals) Growth Rank : 7 (As of Jan. 15, 2025) - GuruFocus.com
Jazz Pharmaceuticals plc (JAZZ): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
Serina Therapeutics Appoints Former Jazz Pharmaceuticals Finance Executive Karen Wilson to Board - StockTitan
Acute Lymphocytic Leukemia Pipeline Analysis 2024: FDA - openPR
With EPS Growth And More, Jazz Pharmaceuticals (NASDAQ:JAZZ) Makes An Interesting Case - Simply Wall St
Jazz Pharmaceuticals CEO sells shares worth $185,145 By Investing.com - Investing.com Nigeria
Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells 1,500 Shares of Stock - MarketBeat
Jazz Pharmaceuticals CEO sells shares worth $185,145 - Investing.com India
Centre Asset Management LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $177.00 Consensus Target Price from Analysts - MarketBeat
JPMorgan Chase & Co. Lowers Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Principal Financial Group Inc. Sells 66,821 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Sentiment Still Eluding Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Simply Wall St
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025 (NASDAQ:JAZZ) - Seeking Alpha
Drug Resistant Epilepsy Market Growth, Trends & Key Players - openPR
Barclays PLC Has $4.37 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Sanctuary Advisors LLC Acquires 9,804 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Akari Therapeutics Names Interim CEO Patel as Permanent Chief, Adds Jazz Pharma Veteran to Board - StockTitan
Jazz Pharmaceuticals CEO to retire by end 2025, search begins - Investing.com Australia
Public Employees Retirement System of Ohio Makes New $2.49 Million Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals CEO to Present Strategic Vision at JP Morgan Healthcare Conference 2025 - StockTitan
Big Peninsula drugmaker on the hunt for new CEO - The Business Journals
Jazz Pharmaceuticals CEO to Retire, Succession Search Underway - Sleep Review
Graft-Versus-Host Disease Market on Track for Major Expansion - openPR
Jazz Pharmaceuticals Announces CEO Succession Plan - PharmiWeb.com
Bruce Cozadd to retire as Jazz’s CEO - BioCentury
Jazz Pharmaceuticals CEO to retire - MSN
Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 - Marketscreener.com
Jazz Pharmaceuticals CEO to retire by end of 2025 - Investing.com South Africa
Jazz to search for new chief as CEO plans retirement - BioPharma Dive
Jazz Pharmaceuticals CEO to Step Down After Two Decades of Transformative Leadership - StockTitan
Franklin Resources Inc. Acquires 48,708 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat
Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist? - Yahoo Finance
Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch - Yahoo Finance
Morgan Stanley boosts Jazz Pharmaceuticals stock rating, sees upside with Ziihera launch - Investing.com Nigeria
Jazz Pharmaceuticals retains stock target, Overweight rating on FDA approval By Investing.com - Investing.com Nigeria
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):